Literature DB >> 3753939

Hyperphagic and anorectic effects of beta-carbolines in a palatable food consumption test: comparisons with triazolam and quazepam.

S J Cooper.   

Abstract

The triazolobenzodiazepine triazolam (0.1-1.0 mg/kg i.p.) and quazepam (0.3-30.0 mg/kg i.p.) were administered to non-food-deprived rats which had been partially-satiated on a palatable diet. In a subsequent 30 min feeding test, both compounds produced a significant increase in the level of food consumption. While triazolam had a dose-related effect and produced a 151.5% increase in the level of food intake, quazepam exerted only a partial effect, achieving a 73.9% increase in food intake at 3.0 mg/kg but no additional increase in food intake at higher doses. The two beta-carbolines, ZK 93423 (0.1-3.0 mg/kg i.p.) and ZK 91296 (1.0-30.0 mg/kg i.p.), a full agonist and a partial agonist at benzodiazepine receptors respectively, also produced significant increases in food consumption under the same experimental conditions. ZK 93423 had effects which were similar to those of triazolam, ZK 91296 had effects similar to quazepam. The beta-carboline benzodiazepine inverse agonist FG 7142 (10.0 mg/kg i.p.) had an anorectic effect in non-food-deprived rats given 30 min access to the highly palatable diet. This effect was reversed by the beta-carboline benzodiazepine receptor antagonist ZK 93426 in a dose-dependent manner. These results emphasize that within the series of beta-carboline ligands for benzodiazepine receptors, their characterization in terms of agonists, antagonists and inverse agonists has validity with respect to the behavioural response of palatable food consumption in non-food-deprived rats.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3753939     DOI: 10.1016/0014-2999(86)90466-8

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  9 in total

1.  The 5-HT1A agonist 8-OH-DPAT increases consumption of palatable wet mash and liquid diets in the rat.

Authors:  C T Dourish; S J Cooper; F Gilbert; J Coughlan; S D Iversen
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

2.  Enhanced sucrose pellet consumption induced by benzodiazepine-type drugs in squirrel monkeys: role of GABAA receptor subtypes.

Authors:  Angela N Duke; Donna M Platt; James M Cook; Shengming Huang; Wenyuan Yin; Bruce A Mattingly; James K Rowlett
Journal:  Psychopharmacology (Berl)       Date:  2006-06-17       Impact factor: 4.530

Review 3.  Psychiatric implications of altered limbic-hypothalamic-pituitary-adrenocortical activity.

Authors:  F Holsboer
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1989

4.  Benzodiazepine-induced hyperphagia: stereospecificity and antagonism by pyrazoloquinolines, CGS 9895 and CGS 9896.

Authors:  S J Cooper; R E Yerbury
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

5.  Effect of the benzodiazepine receptor agonist, zolpidem, on palatable fluid consumption in the rat.

Authors:  K J Stanhope; S Roe; G Dawson; F Draper; A Jackson
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

6.  Reversal of the anorectic effect of (+)-fenfluramine in the rat by the selective cholecystokinin receptor antagonist MK-329.

Authors:  S J Cooper; C T Dourish; D J Barber
Journal:  Br J Pharmacol       Date:  1990-01       Impact factor: 8.739

7.  The effects of chronic chlordiazepoxide administration on ingestion of edible and nonedible substances by rats.

Authors:  A Posadas-Andrews; J Nieto
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

8.  Ro 15-4513 selectively attenuates ethanol, but not sucrose, reinforced responding in a concurrent access procedure; comparison to other drugs.

Authors:  N M Petry
Journal:  Psychopharmacology (Berl)       Date:  1995-09       Impact factor: 4.530

9.  Evidence that d-fenfluramine anorexia is mediated by 5-HT1 receptors.

Authors:  J C Neill; S J Cooper
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.